Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson
Stock Information for Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Loading
Please wait while we load your information from QuoteMedia.